RUTHERFORD, N.J. and LOS ANGELES, July 27, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it received the 2017 North American Frost & Sullivan Award for Precision Oncology Technology Innovation. Cancer Genetics is a leader in the discovery, development and commercialization of unique genomic and biomarker tests that accelerate drug development and clinical trials while also enabling precision oncology in the clinical setting. Frost & Sullivan believes CGI’s global infrastructure, which has been developed through strategic acquisitions, and its unique business model, which incorporates state-of-the-art clinical testing for cancer patients and comprehensive solutions for the biopharma community, have positioned the Company uniquely for diversified growth and access to the oncology community.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
“Our business requires that we balance innovation and execution to meet the dual-edged demands of an increasingly competitive and global environment where high quality and insightful tests are required to make a real impact in oncology care. All of us at CGI are very proud to earn this prestigious award as the leader in technology innovation for precision oncology based on a combination of business model and technology factors. This demonstrates that our team’s focus on impacting patient outcomes in cancer and collaborating with others in the oncology ecosystem produce innovation that is being recognized not only by our customers and clients, but also by leading industry analysts,” stated CGI President and CEO Panna Sharma.
“CGI has a wide variety of assays for genomic and immuno-oncology related biomarkers, applicable across several therapeutic areas, including hematological malignancies, solid tumors, and hereditary cancers,” said Frost & Sullivan Research Analyst Vandana Iyer. “The Company offers a broad range of laboratory services that provide critical genomic and biomarker information for patient care and for clinical trials being performed by biotech and pharmaceutical companies. CGI's recent launches of cutting edge tests, its ability to partner with innovative companies, and its extensive research collaborations with leading academic institutions and cancer centers are a testament to the value and depth of CGI’s commitment to driving industry innovation.”
“CGI is a technology-agnostic company with comprehensive diagnostic capabilities utilizing various platforms,” noted Iyer. “CGI has several ongoing research collaborations with leading oncologists and cancer centers in both solid tumors and hematological malignancies, including kidney cancer, leukemia, non-Hodgkin’s lymphoma, and HPV-associated cancers. The Company constantly strives for diversity and innovation, and has successfully achieved a balance between the two.”
A summary of the report from Frost & Sullivan can be accessed from this link.
ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding the completion, timing, pricing and size of the offering described in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended March 31, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
CONTACT: Investor Relations Contact: Richard Moyer Cameron Associates 535 Fifth Ave., New York, NY 10017 Tel: 212-554-5466 Email: email@example.com